Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1283 and mRNA-1273 in Healthy Adults
NCT04813796Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Mar 2021
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of mNEXSPIKE in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Moderna Inc. Primary endpoints: Solicited Local and Systemic Reactogenicity Adverse Reactions, Unsolicited Adverse Events and 1 more. Started Mar 2021; status: completed.
02
Drugs
mNEXSPIKE
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04813796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04813796.